These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 3566863)

  • 1. Intestinal absorption of 59Fe from neutron-activated commercial oral iron(III)-citrate and iron(III)-hydroxide-polymaltose complexes in man.
    Heinrich HC
    Arzneimittelforschung; 1987 Jan; 37(1A):105-7. PubMed ID: 3566863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of trivalent iron in oral iron preparations. Therapeutic efficacy and iron absorption from simple ferric compounds and high- or low-molecular weight ferric hydroxide-carbohydrate complexes.
    Heinrich HC
    Arzneimittelforschung; 1975 Mar; 25(3):420-6. PubMed ID: 1174047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of iron from oral ferric polymaltose in humans.
    Nielsen P; Gabbe EE; Fischer R; Heinrich HC
    Arzneimittelforschung; 1994 Jun; 44(6):743-8. PubMed ID: 8053973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations.
    Kaltwasser JP; Werner E; Niechzial M
    Arzneimittelforschung; 1987 Jan; 37(1A):122-9. PubMed ID: 3566867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of postabsorptive serum iron increase and erythrocyte-59Fe-incorporation with the whole body retention of absorbed 59Fe.
    Heinrich HC; Fischer R
    Klin Wochenschr; 1982 Dec; 60(24):1493-6. PubMed ID: 6820097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting the absorption of iron from Fe(III)EDTA.
    MacPhail AP; Bothwell TH; Torrance JD; Derman DP; Bezwoda WR; Charlton RW; Mayet F
    Br J Nutr; 1981 Mar; 45(2):215-27. PubMed ID: 6260128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of iron and cyanide from 59Fe- and 14C-labelled hexacyanoferrates(II) in rats.
    Nielsen P; Dresow B; Fischer R; Heinrich HC
    Z Naturforsch C J Biosci; 1990 Jun; 45(6):681-90. PubMed ID: 2400471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bioavailability of iron in oral iron preparations. Principles of duration and dosage (author's transl)].
    Heinrich HC; Gabbe EE
    MMW Munch Med Wochenschr; 1979 Aug; 121(35):1104-8. PubMed ID: 114773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quantitative measurement of 59Fe-absorption. Comparison between iron labelled Parkevit-Fe and an iron-mono-preparation using a wholebody counter (author's transl)].
    Bräuer H
    MMW Munch Med Wochenschr; 1981 Jan; 123(5):181-3. PubMed ID: 6780894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mobilisation of recently absorbed 59Fe in ex vivo perfused rat duodena and the influence of iron status and subsequently absorbed chelators.
    Ettle T; Elsenhans B; Windisch W; Srai SK; Schümann K
    J Trace Elem Med Biol; 2006; 19(4):231-41. PubMed ID: 16443171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the absorption of divalent and trivalent iron in living rats.
    Schäfer S; Forth W
    Arzneimittelforschung; 1984; 34(11):1570-4. PubMed ID: 6543132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Food interaction of oral uptake of iron / a clinical trial using 59Fe.
    Lundqvist H; Sjöberg F
    Arzneimittelforschung; 2007; 57(6A):401-16. PubMed ID: 17691590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intestinal absorption of iron from 59Fe-labelled hexacyanoferrates(II) in piglets.
    Nielsen P; Dresow B; Fischer R; Gabbe EE; Heinrich HC; Pfau AA
    Arzneimittelforschung; 1988 Oct; 38(10):1469-71. PubMed ID: 3196387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose.
    Jacobs P; Johnson G; Wood L
    J Med; 1984; 15(5-6):367-77. PubMed ID: 6599114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron dissociates from the NaFeEDTA complex prior to or during intestinal absorption in rats.
    Zhu L; Yeung CK; Glahn RP; Miller DD
    J Agric Food Chem; 2006 Oct; 54(20):7929-34. PubMed ID: 17002472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of bi- and trivalent oral iron preparations. Investigations of iron absorption by postabsorption serum iron concentrations curves.
    Dietzfelbinger H
    Arzneimittelforschung; 1987 Jan; 37(1A):107-12. PubMed ID: 3566864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal absorption of cationic and anionic ferric colloids and complexes: biochemical, histochemical and morphological observations in rats.
    Akita M; Seno S; Awai M
    Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):1-13. PubMed ID: 2330802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ceruloplasmin and ascorbate in cellular iron release.
    Richardson DR
    J Lab Clin Med; 1999 Nov; 134(5):454-65. PubMed ID: 10560938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dietary iron deficiency and tungsten supplementation on 59Fe absorption and gastric retention from 59Fe compounds in rats.
    Shears GE; Neale RJ; Ledward DA
    Br J Nutr; 1989 May; 61(3):573-81. PubMed ID: 2758011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for regulatory control of iron uptake from ferric maltol across the small intestine of the rat.
    Barrand MA; Callingham BA
    Br J Pharmacol; 1991 Feb; 102(2):408-14. PubMed ID: 2015422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.